MECP2 and myelodysplastic syndrome: While mouse models have been critical in establishing the proof-of-principle for ASO therapy in MDS, these studies have the caveat that each mouse used was genetically identical harboring one additional copy of human MECP2; however, MDS CNVs encompass many genes.